What will the recent accelerated approval of anti-amyloid lecanemab mean for Alzheimers patients, and will it overcome stringent CMS reimbursement policies?
Could the FDA approval of Auvelity usher in a new class of antidepressants? The new oral treatment for depression works with the glutamate receptor NMDA.
In the 1950s and early 1960s, researchers within both academic and governmental institutions extensively investigated the clinical potential of psychedelic drugs, notably both LSD and psilocybin, the psychoactive substance in “magic mushrooms.” This early research aimed to understand the biological underpinnings of schizophrenia and to find new treatments for psychological disorders such as depression, anxiety...